Semaglutide: structure, nomenclature and handling

Semaglutide belongs to the incretin-analogue class, built on the glucagon superfamily scaffold. Native GLP-1 is a short peptide released from the gut, and its defining practical problem as a molecule is fragility: it is cleaved rapidly by dipeptidyl peptidase-4 at the N-terminal end, giving it a very short life in biological media.

The first modification addresses exactly that. Position 8 carries alpha-aminoisobutyric acid — abbreviated AIB — in place of the native alanine. AIB is a non-proteinogenic amino acid with two methyl groups on the alpha carbon, and that additional bulk obstructs the DPP-4 cleavage site sterically. It is a structural block rather than a chemical one.

The second modification is a C18 fatty diacid chain attached at lysine 26 through a short linker. Acylation of this kind promotes reversible binding to serum albumin, which slows clearance considerably. The lipid does not participate in receptor engagement; it changes how long the molecule persists rather than what it binds.

The third is an arginine substitution at position 34. Its purpose is selectivity during synthesis: it removes a second lysine that would otherwise compete for the acylation step, ensuring the fatty acid attaches at position 26 and nowhere else.

Semaglutide is characterized against the GLP-1 receptor, a class B G-protein-coupled receptor. It engages that single receptor family, which is the structural distinction between it and the dual- and triple-receptor analogues in the same class.

Semaglutide appears in the literature under the development code NN9535, and in some sources as NNC0113-0217. Development codes persist in published work long after a generic name is assigned, so both forms are worth recognising when searching databases.

The generic name follows the -glutide stem, shared across analogues of the glucagon-family peptides. Recognising the stem places an unfamiliar name in the right structural family immediately — liraglutide, dulaglutide and semaglutide all carry it.

In the HEEZ catalogue the product title carries the shorthand GLP-1 SM. This is a listing code: GLP-1 for the receptor family it is characterized against, SM for semaglutide. It is vendor shorthand rather than literature nomenclature, and it exists to keep listings compact.

Analytical characterization of semaglutide is more involved than for an unmodified peptide, because the certificate has to confirm not just the sequence but the modifications. Mass spectrometry measures the intact molecular mass, and because the AIB substitution and the C18 diacid each contribute a defined mass increment, the observed figure distinguishes correctly modified material from a peptide missing one of them.

High-performance liquid chromatography separates the main peak from related substances. In an acylated peptide the informative impurities include unacylated peptide, material acylated at the wrong position, and truncated sequences from incomplete coupling. The chromatogram shows how many distinct species are present, which the headline purity percentage alone does not.

Peptide content — sometimes reported as net peptide content — is a separate figure accounting for counter-ions and residual water. For a molecule supplied as a salt it is the number that determines how much actual peptide a nominal 10 mg represents, and it is worth reading alongside purity rather than instead of it.

HEEZ Research supplies semaglutide in a single format: a 10 mg lyophilized vial. There is no second strength in the current catalogue, so the format decision that arises with two-size products does not apply.

Lyophilization removes water and leaves the peptide as a solid cake or powder. A dried peptide is substantially more stable than the same peptide in solution, which is why this is the standard supply form and why no cold chain is needed for transit.

Because semaglutide is a modified peptide of moderate molecular weight, 10 mg represents fewer molar units than 10 mg of a short peptide would. Protocols specified in molar terms need the molecular weight from the certificate of analysis rather than the vial mass alone.

Concentration equals mass divided by volume. A 10 mg semaglutide vial reconstituted with 1 ml of diluent gives 10 mg per ml; with 2 ml, 5 mg per ml; with 5 ml, 2 mg per ml. The arithmetic is the same for any lyophilized peptide.

Bacteriostatic water is the usual diluent where a vial will be entered more than once — its 0.9% benzyl alcohol content is the preservative that permits repeat entry. Sterile water without preservative is used where a single entry is planned.

peptcalc.com performs this conversion directly: enter the 10 mg vial mass and the concentration a protocol calls for, and it returns the volume to add. Working it explicitly is worth the moment it takes, because a concentration error here propagates through every subsequent dilution.

Diluent is introduced slowly down the inner wall of the vial rather than directly onto the cake, and the vial is swirled rather than shaken. Acylated peptides are prone to aggregation under mechanical stress at the air-liquid interface, which presents as cloudiness in an otherwise clear solution.

Sealed lyophilized semaglutide is stable at ambient temperature for the duration of transit, so no cold chain, insulated packaging or ice packs are required in shipping. On arrival the vial goes to refrigeration and is kept protected from light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify. Repeated freeze-thaw cycling is avoided: each cycle is an opportunity for aggregation and for loss of intact peptide.

The fatty acid modification improves persistence in biological media but confers no advantage against the physical degradation routes that matter in storage — aggregation, oxidation, and adsorption to container surfaces. Standard peptide handling applies unchanged.

A certificate of analysis records what an independent facility measured for one specific batch. Its value is that it is batch-specific, so the first check is that the lot number on the document matches the number on the vial in hand.

The identity section compares observed molecular mass against the theoretical mass for the modified sequence. Because the AIB substitution and the C18 diacid each contribute known mass, a result matching unmodified GLP-1 would indicate materially different material.

The purity figure is the HPLC main-peak area as a percentage of total peak area, with the chromatogram attached. For an acylated peptide it is worth looking at whether impurities are a few discrete peaks or a broad cluster, since those suggest different synthesis problems.